^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Th1 epitope positive

    Associations

    News

    Trials
    over3years
    DEVELOPMENT OF A VACCINE TARGETING MDM2 AND CDK4 FOR WELL-DIFFERENTIATED/DE-DIFFERENTIATED LIPOSARCOMA (CTOS 2022)
    Cancer vaccines can generate a strong immune response to recognize and eliminate tumor cells and potentially synergize with other immunotherapies. An effective cancer vaccine will also generate memory cells able to find and eliminate any metastatic disease in the future. We have been able to identify Th1 epitopes in the two main drivers of WD/DD LPS, MDM2 and CDK4.
    Tumor Mutational Burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CDK4 (Cyclin-dependent kinase 4) • CD4 (CD4 Molecule) • IL10 (Interleukin 10)
    |
    TMB-H • TMB-L • Th1 epitope positive